GU Cancers 2024 | Evaluating the role of SBRT in metastatic castrate-resistant prostate cancer

Valerie Fonteyne, MD, PhD, Ghent University Hospital, Ghent, Belgium, discusses the current role of stereotactic radiotherapy in certain patients with metastatic castrate-resistant prostate cancer (mCRPC). Stereotactic body radiotherapy (SBRT) has shown to be effective in producing durable complete responses, and findings from the Phase II ARTO trial (NCT03449719) have additionally demonstrated the utility of SBRT with abiraterone in patients with oligometastatic castrate-resistant prostate cancer. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.